Petros Pharmaceuticals, Inc. (PTPI)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise | - | 1,576,366 | 1,421,471 | |
| Cost of goods and services sold | - | 287,005 | 329,110 | |
| Gross profit | - | 1,289,361 | 1,092,361 | |
| Research and development expense | - | 588,355 | 368,798 | |
| Depreciation, depletion and amortization | - | 739,449 | 717,838 | |
| Selling, general and administrative | 1,800,778 | 2,301,305 | 2,286,630 | |
| Total operating expenses | 1,800,778 | 3,629,109 | 3,373,266 | |
| Loss from continuing operations | -1,800,778 | -2,339,748 | -2,280,905 | |
| Derivative, gain (loss) on derivative, net | - | 202,000 | 1,614,000 | |
| Amount of the cost of promissory notes accounted for as interest expense for debt | - | 158,730 | 114,512 | |
| Interest income | 88,849 | 75,817 | 119,391 | |
| Change in fair value of warrant liability | 329,343 | - | - | |
| Total other income (expenses) | -240,494 | 119,087 | 1,618,879 | |
| Income (loss) before income taxes | -2,041,272 | -2,220,661 | -662,026 | |
| Income (loss) from continuing operations, net of tax | -2,041,272 | - | - | |
| Gain from assignment of subsidiaries and vivus settlement | 6,973,302 | - | - | |
| Gain (loss) from discontinued operations | 500,816 | - | - | |
| Net income (loss) | 5,432,846 | -5,246,715 | -2,734,919 | |
| Preferred stock dividends, income statement impact | - | 1,051,695 | 216,798 | |
| Preferred stock, accretion of redemption discount | - | 1,974,359 | 1,856,095 | |
| Net income (loss) available to common stockholders, basic | - | -5,246,715 | -2,734,919 | |
| Earnings per share, basic | -1.29 | -0.53 | -0.37 | |
| Earnings per share, diluted | -1.29 | -0.53 | -0.37 | |
| Weighted average number of shares outstanding, basic | 25,922,503 | 9,829,793 | 7,388,107 | |
| Weighted average number of shares outstanding, diluted | 25,922,503 | 9,829,793 | 7,388,107 | |